title: Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
abstract: OBJECTIVE
  To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens.
  
  
  METHODS
  Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use.
  
  
  RESULTS
  Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 +/- 0.07%) and placebo-treated (-0.45 +/- 0.07%) patients. However, pramlintide treatment was associated with reductions in mean body weight (-1.50 +/- 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 +/- 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 +/- 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 +/- 3.33%).
  
  
  CONCLUSIONS
  Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.
authors.affiliation: Department of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA. dgmarrer@iupui.edu
authors.forename: David G
authors.initials: DG
authors.lastname: Marrero
authors.forename: John
authors.initials: J
authors.lastname: Crean
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Terrie
authors.initials: T
authors.lastname: Kellmeyer
authors.forename: Maurice
authors.initials: M
authors.lastname: Gloster
authors.forename: Kathrin
authors.initials: K
authors.lastname: Herrmann
authors.forename: Richard
authors.initials: R
authors.lastname: Rubin
authors.forename: Naomi
authors.initials: N
authors.lastname: Fineberg
authors.forename: Orville
authors.initials: O
authors.lastname: Kolterman
mesh_terms: D000328:Adult; D000682:Amyloid / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D058228:Islet Amyloid Polypeptide; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010919:Placebos; D011795:Surveys and Questionnaires
chemical_list: D000682:Amyloid; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D010919:Placebos; C105254:pramlintide